Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Back to my point. How can you tell for sure that the interim data aren’t impressive from an incomplete population at week 6? Phase 2a (200 mg arm) showed ~10% >= 2-point IGA improvement at week 6. That didn’t look impressive to me, but final result showed 35% (PP population).

Withholding bad trial result sounds like a rule violation to me (disclaimer: I’m not sure, LR). If yes, the truth can be found out by questioning the CRO during a class action lawsuit. I doubt Leo will take that risk.

I said the results were not impressive.